US Stock Futures Down Ahead Of Industrial Production Report

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade, ahead of economic data. The Empire State manufacturing index for September will be released at 8:30 a.m. ET, while industrial production data for August will be released at 9:15 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 25 points to 16,881.00, while the Standard & Poor's 500 index futures fell 3.70 points to 1,973.00. Futures for the Nasdaq 100 index dropped 6.25 points to 4,055.75.
A Peek Into Global Markets
European markets were mostly lower today, with the Spanish Ibex Index falling 0.35%, STOXX Europe 600 Index dropping 0.09%. German DAX 30 index rose 0.13%, French CAC 40 Index fell 0.21% and London's FTSE 100 Index dropped 0.22%. In Asian markets, Hong Kong's Hang Seng Index dipped 0.97%, China's Shanghai Composite Index rose 0.31% and India's BSE Sensex tumbled 0.90%.
Broker Recommendation
Analysts at Goldman Sachs downgraded Cree
CREE
from Buy to Neutral. The target price for Cree has been lowered from $60 to $48. Cree's shares tumbled 3.46% to $41.20 in pre-market trading.
Breaking news
  • Mylan MYL today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. To read the full news, click here.
  • Cognizant CTSH today announced that it has entered into a definitive agreement to acquire TriZetto Corporation for $2.7 billion in cash, subject to customary adjustments. Based in Englewood, CO, privately-held TriZetto is a leading provider of healthcare IT software and solutions. To read the full news, click here.
  • Danaher DHR has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion. To read the full news, click here.
  • TG Therapeutics TGTX announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, in combination with Imbruvica® (ibrutinib) for the treatment of Chronic Lymphocytic Leukemia (CLL) in patients with high risk cytogenetics. To read the full news, click here.
Loading...
Loading...
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsGoldman SachsUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...